Tecentriq (Atezolizumab) is a monoclonal antibody that belongs to a class of immune checkpoint inhibitors. It is designed to block the programmed death-ligand 1 (PD-L1) protein, enhancing the immune system's ability to detect and destroy cancer cells. Tecentriq is used in the treatment of various advanced cancers, including lung, liver, breast, and bladder cancers.

Indications:

Non-Small Cell Lung Cancer (NSCLC):

• As a single agent or in combination with chemotherapy for advanced or metastatic cases.

Small Cell Lung Cancer (SCLC):

• In combination with chemotherapy as first-line treatment for extensive-stage disease.

Triple-Negative Breast Cancer (TNBC):

• In combination with nab-paclitaxel for PD-L1-positive, unresectable locally advanced, or metastatic disease.

Hepatocellular Carcinoma (HCC):

• In combination with bevacizumab for patients with no prior systemic therapy.

Urothelial Carcinoma:

• For patients with advanced or metastatic disease who are ineligible for cisplatin-containing chemotherapy.

Tecentriq works by inhibiting the PD-L1 protein on cancer cells, which normally binds to the PD-1 receptor on T-cells to suppress their activity. By blocking this interaction, Tecentriq restores T-cell activity, enabling the immune system to recognize and attack cancer cells.